Soliris 300mg (eculizumab)
Facts of Soliris 300mg (eculizumab) ?
- Medicine Name: Soliris
- Generic Name: eculizumab
- Approval Date: September 23, 2011,
- Company Name: Alexion, Inc
- Available as (Form & Strength): For injectable suspension: lyophilized powder containing 100 mg of paclitaxel formulated as albumin-bound particles in single-use vial for reconstitution.
What are the indications and usage?
- Paroxysmal Nocturnal Hemoglobinuria (PNH): Soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis
- Atypical Hemolytic Uremic Syndrome (aHUS) : Soliris is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.
Trade Name: Soliris®
Eculizumab is the generic name for the trade chemotherapy drug Soliris. In some cases, health care professionals may use the trade name Soliris when referring to the generic drug name eculizumab.
Soliris is a “monoclonal antibody” that binds or attaches to a protein present in the blood. For more detail, see How Soliris Works below.
What Soliris Is Used For:
Soliris is used for the treatment of the blood disorders:
- paroxysmal nocturnal hemoglobinuria (PNH)
- atypical Hemolytic Uremic Syndrome (aHUS)
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.